Highest-materiality recent filing
Mirion board approves new $250M share repurchase program through Aug 2031
Board authorized up to $250M of Class A common stock repurchases, effective Aug 31, 2026 through Aug 31, 2031.
Mirion Q2 revenue up 19.7% to $266.8M; GAAP net income down 4.7% to $8.1M
Revenue $266.8M vs $222.9M YoY (+19.7%); GAAP net income $8.1M vs $8.5M (-4.7%).
Mirion Technologies enters expatriation agreement with President Loïc Eloy; base salary $415K
Loïc Eloy, President Nuclear & Safety Group, seconded from France to US; reports to CEO Thomas Logan.
Mirion Technologies announces stockholder voting results at 2026 annual meeting
All eight director nominees elected with over 186.9M votes for each; broker non-votes were ~13.4M shares.
Mirion Q1 revenue up 27.5% to $257.6M, orders surge 19-42%; reaffirms FY guidance, adj. EPS trimmed
Q1 revenue $257.6M (+27.5% YoY); GAAP net loss $3.4M vs $0.4M income; GAAP EPS -$0.01.
Mirion grants CEO Thomas Logan 2.5M performance stock options tied to relative TSR
Target award of 2,500,000 performance-vesting stock options; maximum 3,750,000 shares at 150% target.
Mirion Q4 revenue $277.4M (+9.1% YoY); guides FY2026 revenue growth 22-24%
Q4 GAAP net income $17.8M vs $15.9M; EPS $0.07 unchanged YoY.
Mirion refinances existing term loans with new $450M tranche maturing 2032
Amendment No. 6 creates $450M Replacement Term Loans maturing June 5, 2032, to repay all prior term loans.
Mirion Technologies completes Paragon Energy Solutions acquisition
Mirion completed acquisition of all membership interests of WCI-Gigawatt Intermediate Holdco, LLC, indirect parent of Paragon Energy Solutions.
Mirion allocates $450M term loan tranche maturing 2032 to refinance existing debt
$450M Replacement Term Loans maturing 2032; margin SOFR+2.00% or ABR+1.00%.
Q3 revenue $223.1M (+7.9% YoY); GAAP net income $3.1M vs loss $14.0M; Adj EBITDA $52.4M (+14.7%).
Mirion closes $410M equity & $375M convertible debt offerings for Paragon acquisition
Common stock offering of 19,906,322 shares at $21.35/share, net proceeds ~$409.7M.
Mirion acquires Paragon Energy Solutions for $585M all-cash
Equity Purchase Agreement to acquire all outstanding equity of Paragon for $585M cash.
Mirion Q2 revenue up 7.6%, GAAP net income $8.5M, raises FY guidance
Revenue $222.9M (+7.6% YoY); GAAP net income $8.5M vs loss $12.0M in Q2 2024.
Mirion refinances $450M term loans with new 2032 tranche; improved pricing and covenant flexibility
New $450M Replacement Term Loans maturing June 5, 2032; proceeds refinance all existing term loans.
Mirion allocates $450M term loans to refinance existing debt; maturity 2032
$450M Replacement Term Loans allocated; expected to mature in 2032.
Mirion prices upsized $400M 0.25% convertible notes due 2030; repays $250M term loan
$400M aggregate principal (including $50M option exercise) of 0.25% convertible senior notes due 2030.
Mirion proposes $300M convertible notes due 2030, plans $450M term loan refinancing
Offering of $300M aggregate principal amount of Convertible Senior Notes due 2030; initial purchasers have option for additional $45M.
Eight directors elected to one-year terms; for votes ranged from 170.9M (John W. Kuo) to 183.9M (Sheila Rege).
Mirion Q1 revenue up 4.9% to $202M; GAAP net income $0.4M vs loss; raises revenue guidance
Revenue $202.0M (+4.9% YoY); GAAP net income $0.4M vs net loss $26.5M in Q1 2024.
Revolving credit commitments raised from $90M to $175M.
Mirion Q4 revenue $254M, GAAP net income $15.9M; reaffirms FY2025 guidance
Q4 revenue $254.3M (+10.4% YoY); GAAP net income $15.9M vs $14.5M loss in Q4 2023.
Mirion 2028 targets: ~$1.1B revenue, 30% Adj EBITDA margin; 2025 guidance: 5.5-7.5% organic growth
2028 targets: revenue ~$1.1B, Adj EBITDA margin ~30%, Adj FCF conversion ~60%.
Mirion Q3 revenue $206.8M (+8.2% YoY); updates FY guidance, narrows FCF range to $65-75M
Q3 revenue $206.8M (+8.2% YoY); GAAP net loss $14.0M ($0.07 loss per share); adjusted EPS $0.08 vs $0.05 YoY.
Mirion Q2 revenue up 5% to $207.1M; loss narrows; raises FY adj. EBITDA guide
Revenue $207.1M (+5% YoY); net loss $12.0M vs $28.4M; adjusted EBITDA $48.8M (+10.2%).
Mirion exchanges 8.5M private warrants for 1.77M shares of Class A common stock
Issued 1,768,000 Class A shares to GS Sponsor II LLC in exchange for 8,500,000 Private Warrants.
Mirion stockholders elect eight directors, ratify auditor, approve say-on-pay at 2024 annual meeting
Elected eight directors; each received >161M votes for, with <11.5M against/abstain.
Mirion completes public warrant redemption; 673,363 warrants redeemed at $0.10 each
Of 18,749,779 warrants outstanding at March 31, 2024, 96.4% were exercised (2,131 for cash, 18,074,285 cashless for 3,976,287 shares).
Mirion enters $694.6M term loan refinancing, maturing 2028
Entered Amendment No. 3 to Credit Agreement on May 22, 2024, refinancing $694.625M Initial Term Loans.
Mirion allocates $694.6M term loan tranche to refinance existing debt, maturing 2028
$694.625M replacement term loans allocated, maturing in 2028; expected close in Q2 2024.
Mirion Technologies Reports Q1 2024 Revenue of $192.6M, Reaffirms Full-Year Guidance
Revenue increased 5.8% to $192.6M in Q1 2024 from $182.1M in Q1 2023.
Mirion redeems all public warrants at $0.10; exercise deadline May 20, 2024
Redemption price $0.10 per warrant; cash exercise price $11.50 per share.
Mirion Q4 2023 revenue up 5.7% to $230.4M, net loss narrows to $15.2M, guides 2024
Q4 revenue $230.4M, +5.7% YoY; net loss $15.2M vs $153.4M loss in Q4 2022 (90.1% improvement).
Mirion subsidiary assigns credit agreement obligations to IntermediateCo; terms unchanged
On Dec 30, 2023, HoldingSub2 assigned all rights and obligations under the Existing Credit Agreement to Mirion IntermediateCo, Inc.
Mirion Q3 revenue up 18.8% to $191.2M; net loss narrows to $12.1M; reiterates FY guidance
Revenue $191.2M (+18.8% YoY); net loss $12.1M vs $47.1M loss in Q3 2022.
Mirion Medical Group President Michael Rossi resigns Nov 1; CEO Logan steps in
Michael Rossi resigns as Medical Group President, effective Nov 1, 2023, to become CEO at another public company.
Mirion Q2 revenue up 12.2% to $197.2M; raises FY revenue growth guidance to 8-10%
Q2 revenue $197.2M (+12.2% YoY); net loss narrowed to $28.4M from $59.3M.
Mirion amends credit agreement to transition from LIBOR to SOFR
Amendment No. 2 dated June 23, 2023 replaces LIBOR with SOFR for USD borrowings.
Director Jyothsna Natauri resigns; Mirion terminates sponsor nomination pact
Jyothsna Natauri resigned from the board effective June 20, 2023 due to leaving Goldman Sachs.
Mirion stockholders approve charter amendments for officer exculpation and supermajority sunset
Nine directors elected to one-year terms at June 6, 2023 annual meeting.
Selling stockholders offer 7M MIR shares at $7.65; company receives no proceeds
Secondary offering of 7,000,000 shares of Class A common stock at $7.65 per share.
Mirion Q1 revenue up 11.6% to $182.1M; net loss widens to $42.9M; reaffirms FY guidance
Revenue $182.1M (+11.6% YoY); net loss $42.9M vs $19.0M loss in Q1 2022.
Mirion selling stockholders sell 9.8M shares at $8.75 in secondary offering
Selling stockholders sold 9,786,153 shares of Class A common stock at $8.75 per share.
Mirion amends bylaws to comply with universal proxy rules and DGCL updates
Adopted amended bylaws effective Feb 28, 2023, addressing SEC universal proxy rules (Rule 14a-19).
T. Rowe Price funds invest $150M for 17.14M shares at $8.75/share (closing price on Feb 17).
Mirion Q4 rev up 22.6% to $217.9M but GAAP net loss $159.7M; FY23 guidance: 6-9% growth
Q4 revenue $217.9M (+22.6% YoY); adjusted revenue growth 20.5%.
Mirion files historical SPAC financials for Oct 2021 close as incorporation reference
Filing includes audited balance sheets of GSAH as of Oct 19, 2021 and Dec 31, 2020.
Mirion Q3 revenues up 11.5% to $160.9M; net loss widens to $50.4M
Q3 revenue $160.9M (+11.5% YoY); adjusted revenue growth 8.7%.
Mirion appoints Michael Rossi as Medical Group President; he joins from Novartis
Michael Rossi appointed President of Mirion Medical, reporting to CEO Tom Logan.
Mirion appoints Dr. Sheila Rege to board, replacing Warren
Christopher Warren resigned from Mirion's Board effective Sept 16, 2022; departure not due to any disagreement.
On October 13, 2023, Mr. Michael Rossi, who has served as the Medical Group President of Mirion Technologies, Inc. (the “Company”), notified the Company of his decision to resign from his position, effective November 1, 2023, in order to assume a CEO role at another public company.
On June 20, 2023, Ms. Jyothsna (Jo) Natauri informed the board of directors ("Board") of Mirion Technologies, Inc. (“Mirion”) of her decision to resign as a director of Mirion, effective as of the close of business on June 20, 2023.
On October 3, 2022, Mirion Technologies, Inc. (the “Company”) announced the appointment of Michael Rossi, as Medical Group President of the Company.
On September 13, 2022, Christopher Warren, a member of the board of directors (the “Board”) of Mirion Technologies, Inc. (the “Company”), notified the Company of his intent to resign from the Board, effective at the close of business on September 16, 2022.
On September 16, 2022, after recommendation by the Nominating and Corporate Governance Committee of the Board, the Board appointed Ms. Sheila Rege, M.D., as a member of the Board, effective immediately, to fill the vacancy created by Mr. Warren’s resignation.
On May 18, 2022, Mirion Technologies, Inc. (the “Corporation”) appointed Christopher Moore as Principal Accounting Officer, effective immediately.
Ms. Kipling Matas, who has served as the Principal Accounting Officer of Mirion Technologies, Inc. (the “Company”), resigned from her position, effective March 23, 2022.
Mr. Brian Schopfer, Chief Financial Officer, will assume the role of Principal Accounting Officer, effective upon her departure.
On February 18, 2022, the Company determined that Michael Freed, who has served as the Chief Operating Officer of the Company, will depart the Company on February 28, 2022 as a result of his position being eliminated.
Max materiality 0.85 · Median 0.60 · Most common event earnings